EVMS Technology Transfer is to transfer to commercial partners the intellectual property developed at EVMS to commercial partners so that the public can benefit from EVMS innovations and inventions.
- Stimulate basic and applied research within the education, research and clinical activities of the school and enhance the interdepartmental collaboration in the basic and clinical sciences areas.
- Motivate discovery of practical applications of research by rewarding inventors for their inventions.
- Evaluate all EVMS and acquired inventions for development, patentability, and licensing potential.
- License and facilitate corporate partners in commercializing EVMS technologies and thus availing the public of EVMS inventions.
- EVMS and EVMS inventors each receive an equitable share of the financial return for inventions resulting from EVMS activity.
- Coordinate and evaluate the use of EVMS inventions in the public interest.
- Lattanzio Telemetric Sensor NCD
- Purine Binding Peptides for Therapeutics
- Method to Inhibit Pancreatic Enzyme Implicated in Diabetes
- Long Lasting, Injectable Birth Control
A Tribute to Gary D. Hodgen, PhD
Professor Gary Hodgen advanced our understanding of folliculogenesis, contraception, preimplantation genetic diagnosis and assisted reproductive technology while mentoring a generation of clinical and basic investigators. For more than three decades, he was engaged in research in the science of reproduction and the discipline of reproductive medicine.
Professor Hodgen relocated from National Institutes of Health to EVMS Obstetrics and Gynecology at Eastern Virginia Medical School to become a professor of Obstetrics and Gynecology and Scientific Director of the Howard and Georgeanna Jones Institute for Reproductive Medicine. In 1986, he was the founding principal investigator of the Contraceptive Research and Development (CONRAD) Program, funded by the United States Agency for International Development. In 1986, this 5-year, $35 million program was the largest biomedical research award ever granted by a federal agency. Dr. Hodgen remained the CONRAD director until 1990. In 1990, he became the President of the Howard and Georgeanna Jones Institute for Reproductive Medicine Foundation. Within the institute, he founded the Technology Development Center in 1994 and focused the last seven years of his career on developing new technologies for reproductive medicine.
During his 17 years at EVMS, Dr. Hodgen was the principal investigator on $258 million worth of sponsored research, and his inventions provided $34 million of patent licensing income.